<SEC-DOCUMENT>0001564590-21-032034.txt : 20210608
<SEC-HEADER>0001564590-21-032034.hdr.sgml : 20210608
<ACCEPTANCE-DATETIME>20210608094556
ACCESSION NUMBER:		0001564590-21-032034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210608
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210608
DATE AS OF CHANGE:		20210608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-HOME FURNITURE, FURNISHINGS & EQUIPMENT STORES [5700]
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19621
		FILM NUMBER:		211001387

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>jan-8k_20210524.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
jan-8k_20210524.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-top:Double 2.25pt;padding-top:1pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /><font style="font-size:12pt;">WASHINGTON, D.C. 20549</font></p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event report:&nbsp;&nbsp;June 8, 2021</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JANONE&#160;INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:9pt;line-height:4pt;margin-bottom:0pt;margin-right:41.28%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nevada</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">000-19621</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">41-1454591</p></td>
</tr>
<tr>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification&#160;No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">325 E. Warm Springs Road, Suite 102</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices and Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: 702-997-5968</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:35%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:43%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.001 par value per share</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JAN</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:43%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NASDAQ Stock Market LLC </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(The NASDAQ Capital Market)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01<font style="font-weight:normal;">&#160;</font>Other Events.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 8, 2021, JanOne Inc. (the &#8220;Company&#8221;) issued a press release announcing <font style="color:#000000;">the successful completion of the initial batch production of JAN101, a patented sustained-release form of sodium nitrite aimed at improving vascular function and reducing neuropathic pain and other conditions resulting from poor blood flow</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.68%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) &#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:89%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:89%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="jan-ex991_14.htm"><font style="text-decoration:none;">Press Release of JanOne Inc., dated June 8, 2021</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SIGNATURES</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.68%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:35%;">
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JanOne Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:89.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Tony Isaac </p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;&#160;Tony Isaac</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.9pt;;text-indent:-30.9pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;&#160;&#160;&#160;President and Chief Executive &nbsp;&nbsp;&nbsp;&nbsp;Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:&nbsp;&nbsp;June 8, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>jan-ex991_14.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
jan-ex991_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gesobne2fkf0000001.jpg" title="" alt="" style="width:261px;height:73px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:12pt;text-transform:none;font-variant: normal;">Successfully Completes Initial Batch Production of JAN101, Demonstrating CGMP-scale Production Capabilities </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LAS VEGAS,&#160;June 8, 2021&#160;/PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the successful completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101 for its upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial batch, produced by manufacturing partner CoreRX, contains approximately 200,000 sustained release tablets and matching placebos of JAN101, a patented sustained-release form of sodium nitrite aimed at improving vascular function and reducing neuropathic pain and other conditions resulting from poor blood flow. JAN101 is highly selective, acting only in damaged tissue.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Completion of the CGMP batch is an exciting achievement as we advance toward our planned Phase 2b PAD trial for JAN101,&#8221; said Tony Isaac, President and Chief Executive Officer of JanOne. &#8220;With CGMP compliance, we&#8217;ve proven our ability to economically scale-up production of JAN101 while preserving the product&#8217;s identity, strength, quality, and purity. We are now focused on bottling and labeling JAN101 for distribution to clinical test sites and engaging a contract research organization (CRO) to manage our Phase 2b trial, including the recruitment of subjects.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commenting on potential indications for JAN101, Isaac added, &#8220;Therapeutic options available for patients with PAD are extremely limited, and we believe our solution has the potential to transform the standard of care to an easy twice-a-day pill that substantially improves moderate to severe PAD and minimizes pain associated with the disease. We are also exploring the potential of JAN101 as a treatment for other conditions involving vascular complications, including chronic kidney disease, and, with our initial batch, we now have additional product available for collaborations with independent investigators on this and additional indications.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Food and Drug Administration (FDA) regulates the quality of pharmaceuticals through its main standard CGMP. Completion of CGMP production signifies that JanOne is fully compliant with the FDA&#8217;s formal regulations regarding the design, monitoring, control, and maintenance of manufacturing&#160;processes and facilities for JAN101.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">About JanOne</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk68639173"></a>JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate, JAN101, is for potentially treating peripheral artery disease (&#8220;PAD&#8221;), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase&#160;2b&#160;trials are expected to begin in the near future. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions,<a name="_Hlk68639173"></a> and neuropathic pain. For more information, visit&#160;<font style="text-decoration:underline;">www.janone.com</font>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking and Cautionary Statements</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including statements relating to the commencement of the upcoming Phase 2b trials and whether JAN101 can treat other conditions involving vascular complications, including chronic kidney disease. These forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;aims,&#8221; &#8220;upcoming,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;expected,&#8221; &#8220;potential,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates&#8221; and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report on Form 10-K for the fiscal year ended&#160;January 2, 2021&#160;and other SEC filings (available at&#160;http://www.sec.gov). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations &amp; Media Contact<br /><font style="font-weight:normal;">IR@Janone.com<br />1 (800) 400-2247</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gesobne2fkf0000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gesobne2fkf0000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "" = # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MJO>WMOIUE+>7<JQ01+N=F[?_ %Z!I.3LMRMK>M6F@Z7+?WC81!A5'5V[*/<U
MX??^./$%]?37*ZE<6ZNV5AAD*J@[ 4WQ;XIN/$^J&9LQVD65MX<_='J?<]ZY
M^O/K5G)VCL?>Y3D\,-3YJR3F_G;R_P S9_X2WQ%_T&K[_O\ &NX^&.MZIJ>M
MWD5]?W%S&MMN599"P!W#FO+J]"^$7_(P7W_7K_[.M*C)N:U-<VP]&."J.,4G
M;LNY[#1117HGYX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %4=0U:UTY?WSY<CB->6-4M<UL:>OD0$&Y8<GL@_P :XR21Y9&DD8L[')8G
M)->'F.;K#MTJ6LOP7_!/1PF =5<\]%^9MW?BF\F)%N%@3V&YOS-9,MY=3G,M
MQ*_^\Y-045\S6Q=>L[U)-_UV/9IT*=->[$*DCGFB.8Y73_=8BHZ*YTVG=&K2
M>YIV_B#4K<C]^95_NR#=G\>M=#I_B6VNBL=P/(E/&2?E/X]OQKBZ*]##9IB:
M#TE==GJ<M7!4:BVL_(]0HKCM"UUK5UMKIBUN>%8_P?\ UJ['K7UV"QM/%T^>
M&_5=CP<1AY4)<L@HHHKL, HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**SM3U9; K$D9EN&!8(#@ #N3V%9U:L*4>>;LBX0E.7+'<T:*YQ/$%VC;I8;
M:6,<L()064>N,\UO6]Q'=0)/"VZ-QD&LJ&+I5VU!ZEU:$Z>LB6BBBNDQ"L3Q
M%X9MO$T$4%Y=WD4,9W>7 ZJ&/J<J<XK;HI-)JS-*56=*:G!V:."_X5)H/_/W
MJ7_?R/\ ^(KSGQEH=MX=\0/86DDSQ"-7!E(+9/T KZ#KP_XH?\CG)_UPC_E7
M+7IQC"Z1]/D6/Q-?%<E6;:L_T.,KT+X1?\C!??\ 7K_[.M>>UZ%\(O\ D8+[
M_KU_]G6L*/\ $1[V<?[C4]/U/8:**1F5$9W8*JC)). !7I'YL+5>ZO[.Q7==
MW<%NI[RR!!^M>6^+/B;<33266@OY4"Y5KK'S/_N^@]^OTKSJ:>6YE:6>5Y9&
M.6=V+$_4FN:>)2=HZGTF#X<JU8J=:7*NW7_@'T2GBC0'DV+K6GENG_'PO/TY
MYK4CDCFC$D3JZ'HRG(-?+U:&E:YJ6B3B;3[N2$YRR@Y5OJO0U"Q7='76X77+
M^ZJ:^:/I.BO(]<\;P^(_ LL;$6VI1RQEXU8@.,_>7V]NU>>_:9_^>\G_ 'V:
MN6)2>BN<>%X<JUHMU)<K3M:U_P!3Z>HKPWX;3ROXVM%>5V&R3@L3_ :]RK6E
M4YU<\S,L \#65)ROI?:W<**\P^+\LD?]C;'9<^?G:<?\\Z\P^TS_ //>3_OL
MUG4Q')+EL>C@<@>+P\:_M+7OI;L[=SZ>HKQ?P!XDM=!AU>[U&=V&R,1QYRSM
M\W ']:S=?\?:UKDC*D[6=H>!! Q&1_M-U/\ +VH^L1Y;B7#V(EB)4HOW5;WG
MITOHCVVZUC3+%BMWJ-I P[2S*I_(FH(?$NA7!"Q:Q8,Q. OVA<G\,U\X9R<F
MBLOK3['I+A>E;6H[^A]1*P90RD%3R"#UI:^=M!\4ZKX>N%>SN&,(.7MW.8W'
MT['W'->[Z%K5MX@TB'4+7(5^&0]48=5-;TJRGZGAYEE%7 VDWS1?7_,TJJ:E
M>KI]C)<'!(&%![MVJW7(^++HO=16H/RQKO;ZG_ZW\ZPS#$_5L/*:WV7J<.%H
M^UJJ+V,"65YI6ED8L[G+$]S3**LV%HU]>Q6Z\;SR?0=S7PD8RJ345JV?2MJ,
M;O9%K2=%FU-MV?+@4X9R.OL*ZZTT6PLU 2!7;^_(-Q_^M^%6X(8[>!(8E"QH
M, "I*^UP664<-%-J\N_^1\]B,94JO1V0@  P!@56N--L[M<36T;>^,'\QS5J
MBO1G",URR5T<L92B[IV.,U?PZ]DK7%L3) .64_>3_$5A5ZAUKA->TX:??_NQ
MB&4;D'IZBOE<WRR-!>VI?#U78]K XQU'[.>YE5V/AC43<VK6DAS)"/E)[K_]
M;_"N.K0T2Y-KJ]N^<*S;&^AXK@RW$O#XB+Z/1_,ZL9156DUU6IZ!117.^+69
M;6WVDCYST/M7V>*K_5Z,JMKV/GJ-+VM10O:YT5%>9>;)_?;\ZV/#]_'9SW$U
MS(0@BX&<DG(X'O7D4,]C5J*$H63ZW_X!W5<ME"#DI7^1VM0RW5O <37$49_V
MW KC=0\17EXS+$Q@A[*AY/U-8Y))R3DFIQ&?PB[48W\WH52RN35ZCL>BKJ=@
MYPMY 3Z>8*M A@"I!!Z$5YA5JRU&ZL) T$I SRA^Z?J*RI<0/FM5AIY%SRO3
MW)?>>C453TS4(]2LUF3AAPZ_W35ROHZ=2-2*G!W3/)E%PDXRW0445FZKK,&F
M)M/[R<CY8P?U/H*56M"C!SJ.R0X4Y5)<L5=FE5>2^M(3B2ZA0^C2 &N%O=7O
M;YCYLQ"'_EFG"_\ U_QJC7S];B!)VI0OZ_Y'J4\K=O?E]QZ,FI6,APEY 3Z>
M8,U9!!&0<@UYA5FUO[JR;-O,R>JYX/X5-+B'7]Y#3R'/*M/<E]YZ/7.7)5=4
MUD2X$C6A\K/==O./QJSI&OQZ@1#,!'<=@.C_ $_PJYJ.EPZBJEF:.9/N2KU'
MM[BO4K26,HJI0=[._P"#5O74XJ:="HXU=+_U^A@:?#_IE@UWY$,:P&2-D3'F
M#'(8^HZUJ>&0?[,<@$1M,QCS_=X_KFF-H5Q<!8[S46E@0\(L87-;,4200K%$
MH5$&% [5C@<)4A4YI*R5]]W=)=&U96-,37C*/*G=O[NO^8^BBBO8. **** "
MO#_BA_R.<G_7"/\ E7N%>'_%#_D<Y/\ KA'_ "KGQ/P'T'#?^^/_  O]#C*]
M"^$7_(P7W_7K_P"SK7GM>A?"+_D8+[_KU_\ 9UKEH_Q$?4YQ_N-3T_4]AKSC
MXI^(WM;6+1+:3;)<+ON"#R$[+^)SGV'O7H]?._B^_.I>+-2N"VY1.8T/^ROR
MC]!77B)\L++J?)\/X6-?%<\MHZ_/I_F8E !)  R3T%%>J?##PK"UM_;UY$'=
MF*VJL.% X+_7.0/3%<5.#G*R/L\=C88.BZL_DN[.4TWX>>(]2A646:V\;#*F
MX?83^'7]*-1^'GB33HS(;(7"#J;=]Y_[YZ_I7O5%=?U:%CY'_67%<]^56[:_
MYGRZ05)!!!'!!I*]<^*6@6/]EC6HHQ%>+(J2,HXD!]?<>O\ D>1UR5(.$K'U
MN QL<9156*MY>9UWPT_Y'BT_W)/_ $ U[K7A7PT_Y'BT_P!R3_T U[K79AO@
M/D>)?]\7^%?FSR[XQ?\ ,%_[;_\ M.O+:]2^,7_,%_[;_P#M.O+:YJ_\1GTF
M1?\ (OI_/_TIA6]I'@W7=;B$UI8MY#=)92$4_3/7\*VOAIH%CK6KW,U]&)4M
M%5EB8?*S$G!/J!CI7M0    P!T%71H<ZYF<>;9X\)4]C2C>2W;V/#[CX8>)(
M(BZ16\Y'\,4W/ZXKD;BWFM+AX+B)XIHSM='&"I]Q7T_7EWQ=TR%5L-410LK,
M8)"!]X8ROY8/YU56@HQYHF&59[5Q%=4:R6NS1Y;7I?PAOW6^U#3BQ*/&)U'H
M0=I_/</RKS2NY^%)(\72 $C-HX/O\RUC1=JB/7SB"G@:B?:_W'M5>?:U*9=9
MNF]'V_EQ_2O0:\YU/_D*WG_7=_\ T(UQ<0-^Q@O/]#XK*U^\D_(JUTGA& -<
M7,Y'**%'X_\ ZJYNNL\($?9KD=]X_E7C9/%2QD+^?Y'?CVUAY6.DHHHK[@^<
M"BBB@ K#\50"32EEQS%(#GV/'^%;E9?B(_\ $BN/?;_Z$*Y,?%2PM1/L_P #
M?"MJM&W='!TJL58,."#D4E%? 'U!Z<C!XU<=& -<]XN_X];;_?/\JWK;_CUA
M_P!Q?Y5@^+O^/6V_WS_*ON,S=\#-^2_-'S>#5L3$Y*BBM;P]80W^H$3C*1KO
MV]FY[U\90HRK5%3CNSZ&I45.#F^A6L]*O;X;H("4_OMP/S-7'\+ZDJY"Q.?1
M7Y_6NV "J%4  < #M2U]13R##J-IMMGBRS.JW[J5CS*6&2"5HY49'7JK#FF5
MUWBRV5K.*Y ^='VD^Q_^O_.N1KYW'85X6LZ=[KH>MAJWMJ:F;_A2<IJ,D.?E
MD3./<?Y-=C7#>&O^0W#_ +K?R-=S7TV12;PMGT;/'S))5[]T4M4OUTZQ><@%
MONHI[M7G\TLD\S2RL6=SEB>];GBJZ,NH);@_+"O(_P!H\_RQ6!7BYSBW6KNF
MOACI\^IZ&7T%3I<[W8J(TCA$4LS'  &2:W;;PK>2H&FD2'/\/WC5WPK8*(GO
MG7+D[(\]AW-=+79EN3TZE)5:_79'/B\?*$W"GT.1E\(W"KF*YC<^C*5_QK#N
M;6>SF,4\91QV/>O2JS-=L%O=-D.W][$"Z'OQU'XUOC<DI>S<Z&C73N1A\QGS
MJ-35,X-6*L&4D,#D$=J[W1-1_M&P#.?WT9VR>_O^-<#6UX8N3!JPB)^692I^
MHY'^?>O)RC%.CB%'I+3_ ".W'T54I-]5J=M1117VQ\Z%%%% !1110 5X?\4/
M^1SD_P"N$?\ *O<*\/\ BA_R.<G_ %PC_E7/B?@/H.&_]\?^%_H<97H7PB_Y
M&"^_Z]?_ &=:\]KT;X0QYU?49<'Y8%7/U;_ZU<M'^(CZC.7; U/3]4>NU\O2
MR&65Y&^\[%C^-?4-?,=[ ;6^N+<C!BE9"/H<5OBNAX?"S5ZJ]/U(*^C_  W
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M=_QZVW^^?Y5]GFO^YS_KJCY[!?[Q$Y*NA\)?\A"?_KE_45SU=#X2_P"0A/\
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MJO\ LS,/Y7]Z_P R?KF%[_@_\CEZM::YCU2U;TE7/YUO?\(?_P!/_P#Y!_\
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M2-6"Y![\GM_6@!WQ$1SIMFXSY:RD-]2./Y&M7P?-#+X9M!"1^[!1P.S9)/\
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<#5HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
